 In November 21, 2016 it was announced that Selexys was purchased by Novartis.The purchase occurred following receipt of results of the SUSTAIN study, a Phase II trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease (SCD).Terms of the deal could total up to $665 million in upfront, acquisition and milestone payments.